SB
HZNP

Suntrust Banks’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Suntrust Banks’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,095
Closed -$454K – 1344
2015
Q2 		$454K Buy
+13,095
New +$400K ﹤0.01% 884

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Suntrust Banks's HZNP Position: Q3 2015 in Review

Suntrust Banks sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2015, closing a stake of 13,095 shares — an estimated $454K sold.

Suntrust Banks first reported a position in HZNP in Q2 2015 and held it in 1 quarter. The position peaked at $454K in Q2 2015. 223 funds tracked by Wall St. Rank hold HZNP as of Q3 2015.

  • Suntrust Banks reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2015 after selling out during the quarter.
  • Suntrust Banks sold 13,095 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2015, an estimated $454K.
  • Suntrust Banks first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 1 quarter.
  • Suntrust Banks's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $454K in Q2 2015.
  • 223 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2015.

Based on Suntrust Banks's 13F filing for Q3 2015, filed 16 Nov 2015.